PT  |   EN

Prof. Doctor Dulce Brito in an interview for My Cardiology on the benefits of ferric carboximaltose

Benefits of ferric carboximaltose demonstrated in the AFFIRM-AHF study with national impact

The AFFIRM-AHF study demonstrated that treatment with IV iron carboximaltose, in patients stabilized after an episode of acute heart failure (HF) and with iron deficit, was effective in reducing the risk of hospitalization for HF, with a favorable safety profile. In order to know the relevance of the study and the significance of its findings for the current national panorama, My Cardiologia interviewed Prof. Doctor Dulce Brito, coordinator of the telemonitoring project for patients with HF and the RICA-AHF program.

To access the full interview click here.